Loading patent…
AssigneeThe Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc.
InventorsAlison D. O'BRIEN, Angela MELTON-CELSA, Michael SMITH, James SINCLAIR
Estimating the term…
The invention is based on the discovery of the epitope in the Stx2 protein for the 11 E1O antibody. The invention features compositions containing non-full length Stx2 polypeptides that include the 11 E1O monoclonal antibody epitope. The invention also features methods of producing anti-Stx2 antibodies specific for the 11 E1O epitope of the Stx2 protein. Additionally, the invention features methods for treating a subject having, or at risk of developing, a Shiga toxin associated disease (e.g., hemolytic uremia syndrome and diseases associated with E. coli and S. dysenteriae infection) with a polypeptide that includes the 11 E1O epitope or with an anti-Stx2 antibody developed using the methods of the invention. Furthermore, the invention features the detection of Stx2 in a sample using the antibodies developed using the methods of the invention.
A composition for stimulating an immune response against Stx2 comprising a pharmaceutically acceptable carrier and at least one purified polypeptide, said polypeptide comprising:
A composition for stimulating an immune response against Stx2 comprising a pharmaceutically acceptable carrier and at least one purified polypeptide comprising an amino acid sequence having at least 92% identity to the amino acid sequence set forth in SEQ ID NO:
A purified polypeptide comprising:
A purified polypeptide comprising an amino acid sequence having at least 92% sequence identity to the amino acid sequence set forth in SEQ ID NO:
A purified polypeptide, wherein said polypeptide is a fragment of the amino acid sequence of SEQ ID NO:
-62. (canceled)
Dependencies are inferred from the claim text.